Polypharmacy Impairs Rheumatoid Arthritis Outcomes A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significantly lower treatment responses and more serious adverse events (SAEs). https://t.co/QAJYzHEaFv https://t.co/vUeBsLCYNE

Interstitial lung abnormalities (ILA) are found in 7% of Gen. population, most of whom are asymptomatic, but some will progress to ILD, IPF,and increased risk of lung cancer, etc. Finding incidental ILD appropriate screening monitoring, based on risk factors is indicated. https://t.co/kQbhxTAVTm

Data from 2019 National Health Survey on 87,678 ppl -- 21.6% had chronic back pain. Chronic LBP assoc w/ multimorbidity in 62% (esp. CV dz, arthritis, & depression) https://t.co/LFdWr0s6tg https://t.co/Enj162VYJl

Chronic urticaria (CU) may be a presenting feature of an autoinflammatory syndrome (monogenic or multifactorial) - disorders to consider: cryopyrin-associated periodic (CAPS), Schnitzler, Still's disease, & neutrophilic urticarial dermatosis https://t.co/GKYqFzX6A0 https://t.co/QEEaw9zNjH

HLA-B27: still the most important genetic factor in axSpA susceptibility, but has lower frequency African American, South American & Middle Eastern pop. B27 discerns clinical subsets of SpA and PsA, particularly acute anterior uveitis or axSpA with psoriasis, https://t.co/S4s0NvuwNY

High-Resolution CT in CTD-Interstitial Lung Disease A systematic review and meta-analysis examined the role of high-resolution computed tomography (HRCT) in diagnosing and characterizing interstitial lung disease (ILD) associated with connective tissue diseases (CTDs). https://t.co/9FmEe6BgN7

Our final webinar in this month's Rheum to Breathe: ILD campaign brings together ILD experts to discuss best practices in diagnosis, screening, and monitoring, covering: tools, labs, and imaging; timing and frequency of screening; ILD screening in RA; and, referral strategies. https://t.co/Culzv9bSD4

Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the https://t.co/n8S0N2wTqu

Post hoc analyses of (FUTURE 5) 541 active PsA pts Rx w/ secukinumab shows NO radiographic progression through 2 years of SEC was assoc with achieving LDA at Week 104. https://t.co/IyCsJOm9PS https://t.co/PgDKanxaNU

Report of 54 Sjögren dz pts w/ cutaneous vasculitis (CV); most had cryoglobulinemic vasculitis & hypergammaglob.vasculitis. Sjogrens w/ CV had higher risk of lymphoma. Type II cryoglob. vasculitis incr risk of mortality/lymphoma, renal dz, peripheral nerve involvement https://t.co/Yd1iu9ZJX0